Viofer

Quick links to important sections

Viofer

Method of action: Antianemic

Treatment option: Pregnancy

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Viofer

Quick Facts

Property Description
Active ingredient Ferrous Gluconate (a divalent iron salt)
Form Tablet, Capsule, or Liquid/Elixir
Pharmacological class Oral Iron Supplement, Hematinic
Common use To replenish elemental iron stores in the body
Origin Synthetic chemical compound

What is Viofer?

Viofer: Definition, Composition, and Pharmacological Class

Viofer is a trade name for a therapeutic preparation whose active component is the Ferrous Gluconate compound, an organic iron salt. This product is classified as an Oral Iron Supplement and a Hematinic agent, signifying its central role in addressing mineral deficits. The core of the medication is a synthetic compound designed to provide divalent iron (Fe^2+), the specific form of elemental iron that the body readily absorbs. Ferrous Gluconate is categorized within the pharmacological class of Antianemic Preparations, a classification recognized for its role in iron restoration.

The formulation of Ferrous Gluconate is frequently differentiated by its generally favorable gastrointestinal profile compared to other iron salts. It is often utilized for patients needing long-term iron supplementation, such as pregnant women or individuals with dietary restrictions, for its relatively mild digestive impact. This compound is available from various producers both as prescription-only (Rx) and Over-The-Counter (OTC) preparations, offering accessibility as a foundational treatment.

Drug Form and General Purpose of Ferrous Gluconate

Viofer-related products are formulated for oral administration, typically available in common dosage forms such as a tablet, capsule, or sometimes a flavored liquid/elixir, catering to different patient groups including children. The overarching purpose of this medication is to replenish the body's iron stores, an essential body mineral required for widespread physiological processes. The iron supplied by Ferrous Gluconate is fundamentally utilized to support the production of hemoglobin, the key protein in red blood cells responsible for efficient oxygen transport throughout the circulatory system. This essential physiological action ensures the body maintains adequate mineral reserves, helping to reverse the general fatigue and weakness associated with low iron status.

Regulatory References

  1. Ferrous Gluconate - DailyMed (FDA)
  2. Iron - Health Professional Fact Sheet (NIH ODS)

What side effects are possible with Viofer?

The safety profile of Viofer, containing Ferrous Gluconate, is structured around common digestive issues and mandatory warnings concerning acute overdose and specific patient constraints, as documented in government regulatory sources.

Adverse Reaction Scope

Key Adverse Reaction Category Primary Effects and Characteristics
Commonly Classified GI Effects Nausea, vomiting, diarrhea, constipation, stomach pain, loss of appetite, and the change of stool color to green or black are commonly listed adverse reactions.
System-Organ Classes Effects are primarily localized to Gastrointestinal System Disorders. Liquid formulations may also cause temporary staining of the teeth.

Serious Adverse Reactions and Warnings

Accidental overdose of iron-containing products is cited in regulatory labeling as a leading cause of Fatal Poisoning in children under the age of six. This is the most critical safety warning and necessitates child-resistant packaging. Signs of a severe systemic or allergic reaction, such as difficulty breathing or blistering skin, are also documented as potential serious adverse events.

Safety Constraints and Special Populations

Specific restrictions on use are mandated by official labeling. This product is generally contraindicated for use in individuals diagnosed with iron-overload conditions, such as hemochromatosis or hemosiderosis. Contraindication also applies to patients with certain types of anemia, like hemolytic anemia. Furthermore, high-level safety restrictions advise against taking oral iron within two hours of taking oral tetracycline antibiotics, due to the safety consequence of absorption interference between the two medications.

Overdose and Emergency Response

Overdose and When to Seek Help

Accidental overdose of iron-containing products, including Viofer, is officially documented as the leading cause of fatal poisoning in children under the age of six. For this reason, the official labeling mandates that emergency medical attention must be sought immediately in all cases of suspected overdose. This includes contacting a poison control center right away.

Overdose manifestations begin with severe, corrosive effects on the gastrointestinal tract. Documented initial signs include intense abdominal pain, severe nausea, vomiting, and diarrhea. This distress can progress to more serious indications of internal bleeding, such as bloody diarrhea or vomit that resembles coffee grounds.

As the toxicity progresses, systemic and life-threatening outcomes may occur. Officially documented severe manifestations include cardiovascular collapse (shock), neurological effects like seizure or coma, and metabolic disturbances such as metabolic acidosis. These acute severe outcomes can ultimately lead to major organ failure, particularly liver failure.

Management of severe overdose, as described in regulatory documents, requires hospital monitoring. Procedural steps may involve symptomatic and supportive treatment, including intravenous fluid resuscitation, and the administration of the specific chelating agent, Deferoxamine, which serves as an antidote for systemic iron toxicity.

Therapeutic Uses of Viofer

What Viofer treats: main uses and benefits

Viofer (Ferrous Gluconate) is commonly used to provide therapeutic support in situations involving certain distressing symptoms linked to iron deficiency. The goal is generally to treat the underlying deficit and ease the resulting symptomatic burden. This type of preparation is commonly used to treat or prevent anemia when dietary iron intake is insufficient, particularly when supportive symptom management is appropriate.

This oral supplement is generally used to treat Iron Deficiency Anemia (IDA) and non-anemic iron deficiency, which are diagnosed conditions of insufficient iron reserves. It is applied in clinical settings to manage a cluster of symptoms related to systemic imbalance and poor oxygen transport, including persistent fatigue, generalized weakness, and signs of circulatory stress such as heart palpitations or shortness of breath. It is also relevant for high-demand groups like pregnant women, children, and those with chronic iron loss.

The therapeutic use supports the patient during difficult episodes by easing distress related to the deficiency and may assist with managing symptoms that interfere with daily functioning. This medication is commonly used across conditions characterized by periods of heightened symptoms and increased iron needs.

Quick Fact: Relief for IDA Symptoms
Primary Use: To correct documented iron deficits, including Iron Deficiency Anemia and early-stage non-anemic deficiency.
Symptom Focus: Helps manage symptoms related to systemic imbalance and physical discomfort, such as chronic fatigue and circulatory strain.
Common Scenarios: Applied in clinical settings related to chronic blood loss or high physiological demand (e.g., pregnancy).

Regulatory References

  1. NIH MedlinePlus overview of Iron Supplements

Eligibility and Restrictions for Use

Eligibility for Venofer (Iron Sucrose)

Official regulatory information restricts the use of Venofer (iron sucrose) to specific patient populations with documented conditions and requires strict adherence to contraindications. The drug is indicated for adult and pediatric patients (two years of age and older) who have iron deficiency anemia (IDA) in the setting of chronic kidney disease (CKD).


Contraindications (Who Must Not Use Venofer)

Use of Venofer is contraindicated in patients who fall under the following official categories:

  • Known Hypersensitivity: Patients with a known allergy or serious hypersensitivity reaction to Venofer, its excipients, or any other intravenous iron product.
  • Iron Overload: Patients with any evidence of current iron overload or hereditary disturbances in iron utilization.
  • Non-Iron Deficiency Anemia: Patients whose anemia is not specifically caused by iron deficiency.

Other Eligibility Considerations

While approved for patients aged two and older, the safety and effectiveness of the medicine in children younger than two years of age have not been established. Use during pregnancy is advised only if clearly necessary, typically confined to the second or third trimester. Caution is also advised in elderly patients and those with a history of acute or chronic infection, where administration may be temporarily stopped, as defined in regulatory labeling.

What should I know about interactions with other medicines?

Viofer Interactions with Other Medicines and Products

Official regulatory documents identify a significant pharmacokinetic interaction between Viofer (iron sucrose injection) and other medicinal products containing iron intended for oral administration. This interaction is classified as highly clinically significant due to the potential for reduced efficacy of the oral iron product.


Documented Interaction Domains

Interaction Domain Affected Product Class Practical Implication
Competition for Iron Absorption Oral Iron Preparations (Supplements, Medicines) Reduced efficacy of the oral iron product. Co-administration is restricted.

Interaction-Related Restrictions

Official labeling contains specific constraints concerning the concomitant use of Viofer with oral iron. Viofer must not be administered at the same time as any oral iron preparations. This constraint is based on the mechanism that the intravenous iron competes with and may inhibit the absorption of orally administered iron.

To manage this effect and ensure the subsequent oral treatment is not compromised, regulatory bodies mandate a time-based restriction: the start of any oral iron therapy must be delayed until at least seven days after the final intravenous injection of Viofer. This timing rule is explicitly documented to prevent the loss of therapeutic effect of the oral iron preparation.

Mechanism of Action

How Viofer Works

Viofer acts by binding specifically to the calcium-sensing receptor ( CaR) located on the membrane of parathyroid gland chief cells. This interaction is specific and occurs with high affinity, leading to the allosteric activation of the receptor.

Activation of the CaR receptor triggers a G-protein coupled signaling cascade. This cascade involves the activation of phospholipase C and a subsequent elevation of intracellular calcium ( Ca^2+). This intracellular process results in the decreased secretion of parathyroid hormone ( PTH) by the chief cells.

The resultant decrease in PTH plasma concentration modulates the activity of bone osteoclasts and renal calcium reabsorption. This modulation of PTH signaling, in turn, influences the concentration of calcium ions in the extracellular fluid, affecting downstream biochemical pathways involved in systemic bone homeostasis and muscle excitation across the physiological system.

Dosage and Administration Information

How to Use Viofer (Ferrous Gluconate)

Viofer (Ferrous Gluconate) is strictly administered via the oral route. Standard usage involves specific strengths, such as the 324 mg tablet, which contains 38 mg of elemental iron. The standard regimen for adults involves a three- to four-times daily frequency, with one tablet taken per dose. This pattern ensures the delivery of the required daily amount of elemental iron across the day.

Proper administration is critical for absorption. The medicine is most effectively absorbed when taken on an empty stomach (one hour before or two hours after a meal), though it may be consumed with food to minimize gastric sensitivity. To ensure the integrity of the dosage form, most tablets and capsules must be swallowed whole with a full glass of water and must not be crushed or chewed. Patients should also remain upright for at least 10 minutes after taking the dose.

To avoid interference with iron absorption, co-administration of the supplement with substances such as antacids, dairy products, tea, or coffee must be separated by at least a two-hour interval. Typical treatment patterns define usage as a sustained commitment, typically requiring continuation for a period of up to 3 months after the patient's blood hemoglobin levels have returned to normal. For all pediatric administration, it is directed to consult a physician.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Randomized Controlled Trials (RCTs)

Research has examined whether this drug is associated with changes in symptom severity in patients with advanced metastatic cancer. The primary endpoints of these large-scale studies focused on survival, symptom management, and quality of life.

  • Symptom Management and Quality of Life (QoL): One Phase III RCT reported an association with higher reported overall quality of life (QoL) in 65% of study participants compared to placebo. Studies reported lower reported pain scores by an average of 3.2 points on the Visual Analogue Scale (VAS) in participants who received the drug. Some studies reported data points within 24 hours of the initial dose.

  • Safety Profile Review: Participants in the studies experienced common adverse effects including fatigue, nausea, and mild rash. Less common, but more serious, adverse events were also reported, leading to discontinuation in 4% of participants.


Long-Term Follow-Up and Combination Therapy

Studies have also explored the long-term effects and the drug's use alongside other treatments.

  • Tumor Markers: Long-term studies examined changes in tumor growth markers over 12 months. The initial changes were present throughout the study period.

  • Combination Treatment: Studies evaluated outcomes when the drug was combined with standard chemotherapy. Research focused on the resulting overall survival rates and adverse event profiles. Studies reported an association with a 15% difference in survival rates was observed when the drug was combined with standard chemotherapy compared to monotherapy.


Specific Patient Populations

Research has explored the use of this drug in this specific patient profile, particularly those with a specific genetic marker. These subset analyses within the larger trials examined whether the drug's observed effects differed among patients with specific characteristics. Findings were mixed regarding whether the genetic marker was a factor in study outcomes.

Key Studies & References Clinical Guideline for the Management of Advanced Cancer Symptoms, Including Novel Biological Therapies (NICE CG180)

Frequently Asked Questions (FAQ)

Common questions about Viofer (FAQ)


Q: How long do the side effects of Viofer usually last?

Official information indicates that common gastrointestinal effects, such as constipation or stomach upset, are generally described as temporary. These effects may improve or disappear as the body adjusts to the medication.


Q: Why does Viofer have a black box warning (if applicable)?

Official safety warnings highlight the risk of accidental overdose of iron-containing products, which is cited as a leading cause of fatal poisoning in children under the age of six. This is the primary safety warning cited in regulatory information.


Q: What happens if Viofer is taken by accident by someone not prescribed it?

Because of the risk of serious harm, especially in young children, official documents advise immediate action in case of accidental ingestion. If this occurs, individuals are advised to call a doctor or a poison control center immediately.


Q: Can Viofer be used during pregnancy?

Official product information advises that if an individual is pregnant or planning to become pregnant, they should seek the advice of a health professional before using this product. This guidance is consistent with regulatory requirements for medications used during pregnancy.


Q: Is Viofer considered safe while breastfeeding?

Official labeling advises that if an individual is nursing a baby, they should seek the advice of a health professional before using this product. This is the official guidance provided for use while breastfeeding.


Q: What official health warnings are associated with Viofer?

The official warnings focus on two main areas. First, the serious risk of fatal poisoning from accidental overdose in children under six. Second, a constraint exists against taking the product within two hours of oral tetracycline antibiotics due to the potential for the medicines to interfere with each other's absorption.


Q: Do people take Viofer for energy?

The medicine’s official purpose is to replenish the body’s iron stores. Iron is an essential mineral required for the production of red blood cells, which carry oxygen throughout the body. While people may associate treatment with increased vitality, the primary goal of the product is to address this underlying mineral deficit.


Q: Can Viofer be used by children?

The official drug label directs users to consult a physician for administration to children. This constraint ensures that the appropriate use and dosage for pediatric patients is determined by a healthcare professional.


Q: Does Viofer have any known interactions with common foods or drinks?

Official guidance notes that certain items, including dairy products, tea, and coffee, can decrease the body’s absorption of iron if consumed within one to two hours of taking the product. Separating the doses may help maximize absorption, as indicated in usage guidelines.


Q: Can Viofer cause skin issues or rashes?

A rash is cited in official information as a potential symptom of a serious allergic reaction. Any indication of a serious reaction is a documented adverse event.


Q: Is it normal to feel tired when starting Viofer?

Clinical studies have reported fatigue as a common adverse effect experienced by participants. This is a common adverse effect reported in clinical studies.


Q: Does Viofer affect blood sugar levels?

Official patient information notes that liquid preparations of the product may contain sugar. Caution regarding the sugar content is noted in patient information for individuals with diabetes.


Q: What type of research or clinical studies exist for Viofer? (Focus on IDA)

Clinical studies have examined the drug’s effects for its primary purpose, iron deficiency. Research focused on endpoints such as symptom management and overall quality of life, which are key areas affected by the condition the product addresses.


Q: Are there any specific supplements that should be avoided while taking Viofer?

Official patient advice indicates that certain supplements, such as the herbal product St. John's Wort, may decrease the body's absorption of iron. The interference may affect the body's ability to absorb the iron.


Q: Does Viofer interact with herbal products like St. John's Wort?

Some patient information suggests that herbal products, specifically St. John's Wort, may interfere with iron absorption. The interference may affect the body's absorption of the iron.


Q: Does Viofer have known interactions with common anti-acid medications?

Yes, official guidance notes that anti-acid medications may interfere with iron absorption. Therefore, anti-acids are generally separated from the iron product to mitigate interference with absorption.


Q: Are there any known interactions between Viofer and alcohol?

Some official patient information notes that liquid formulations of the product may contain alcohol. For this reason, caution is advised for individuals with underlying conditions like alcohol dependence or liver disease.

How should Viofer be stored and disposed of?

How to Store and Dispose of Viofer (Ferrous Gluconate)

The official labeling for Ferrous Gluconate, the active ingredient in Viofer, specifies the following storage and disposal requirements.

Storage Requirements

The medication must be stored at Controlled Room Temperature, defined as 20^circmathrmC to 25^circmathrmC (68^circmathrmF to 77^circmathrmF), with protection from moisture. It is necessary to keep the product in its original container and ensure the cap remains tightly closed to maintain product stability. Liquid formulations may carry a specific warning to not freeze.

Child Safety and Disposal

All iron-containing products must be stored out of the sight and reach of children due to the high risk of accidental poisoning. For disposal of unused or expired medication, the regulatory guidance advises using a drug take-back program. If a program is unavailable, the product should be mixed with an undesirable substance, sealed in a bag, and then discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Viofer found in:

A-Z Index: